CPRX: Catalyst Corp Forward Price-to-Revenue Multiple
Catalyst Pharmaceuticals combats neuromuscular pathologies through alliances with scientific centers. Licensing deals with global biopharma behemoths support growth, while the environmental profile is based on audits of external contractors. The forward P/S metric visualizes the market valuation relative to expected revenue, with 5.10 becoming the new value of the indicator, determining the current business value.
Metric breakdowns and analytics for Catalyst Corp (CPRX)
- stock price and consensus target price:
- market capitalization information:
- business book valuation details:
- debt and solvency information:
Total Debt to Capital Catalyst Pharmaceuticals|CPRX - Long-Term Debt to Capital|Short-Term Debt to Equity Catalyst Pharmaceuticals|CPRX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Catalyst Corp|CPRX - Company Long-Term Liabilities|Company Short-Term Debts Catalyst Pharmaceuticals|Quick Ratio catalystpharma.com
- business earnings and investment ratios data:
CPRX - Net Income|Projected Future Earnings Catalyst Pharmaceuticals|CPRX - Market Cap to Earnings|Projected Price to Earnings Catalyst Pharmaceuticals Inc|CPRX - PEG Multiple|Enterprise Value to EBITDA Ratio Catalyst Corp|CPRX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Catalyst Pharmaceuticals|CPRX - Net earnings per share for the last four quarters|Quarterly EPS earnings growth catalystpharma.com|CPRX - Net earnings per share growth this year|Earnings growth forecast for next year Catalyst Pharmaceuticals
- sales volume and revenue information:
Summary company analysis:CPRX (Catalyst Pharmaceuticals, Inc.)
This indicator compares the current market value of Catalyst Pharmaceuticals (CPRX) with projected revenue, allowing for the identification of asset overvaluation before actual financial reporting changes occur. Analyzing the expected price-to-sales ratio is critical for Catalyst Pharmaceuticals (CPRX), as reliance on a single drug leaves the company vulnerable to patent disputes, which could turn speculative growth into a value trap.
Competitors of Catalyst Pharmaceuticals (CPRX)
Biogen - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NBIX (Neurocrine)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Corp)|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|Future Price to Revenue XENE (xenon-pharma.com)|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|SUPN: Forward Price to Sales|Forward P/S Multiple DNLI|Forward P/S Multiple Harmony Corp (HRMY)|Price-to-Projected Revenue Ratio Biohaven Ltd. BHVN|Forward Price to Sales AMLX|TRVI - Price-to-Projected Revenue Ratio|Praxis Precision Medicines Inc (PRAX) - Forward Price-to-Revenue Multiple|AVXL: Forward P/S Multiple|CeriBell EEG (CBLL) - Forward P/S Multiple|PRTA (Prothena Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Alector Therapeutics (ALEC)|Forward P/S Multiple ANNX|OMER - Market Cap to Future Revenue Ratio|Neurogene Corp - Forward Price-to-Revenue Multiple|Forward P/S Multiple AC Immune Inc ACIU|VYGR: Forward Price-to-Revenue Multiple|neumoratx.com - Price to Expected Revenue Ratio|SCLX: Forward P/S Multiple|TVGN - Market Cap to Expected Sales Ratio|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cognition Therapeutics Inc. (CGTX)|Forward P/S Multiple IKT|Forward P/S Multiple cassavasciences.com (SAVA)|Price-to-Projected Revenue Ratio Assertio ASRT|Coya Therapeutics Inc - Price-to-Projected Revenue Ratio|VTGN - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Ovid Therapeutics Inc. OVID|ABOS: Forward P/S Multiple|Forward Price-to-Revenue Multiple cervomed.com|Price-to-Projected Revenue Ratio Alterity Therapeutics Ltd.|Clene Nanomedicine - Future Price to Revenue|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|JUNS (Jupiter Neurosciences, Inc.) - Forward Price to Sales|Relmada Therapeutics - Forward Price-to-Revenue Multiple|ANVS: Market Cap to Projected Revenue|GRCE - Price-to-Projected Revenue Ratio|AIFF (Firefly Neuroscience, Inc.) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|Market Cap to Future Revenue Ratio NeuroSense Therapeutics Ltd. (NRSN)|Forward Price-to-Revenue Multiple RVPH|Forward P/S Multiple MetaVia, Inc.|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|HSDT (heliusmedical.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Market Cap to Future Revenue Ratio|Minerva Neurosciences - Forward P/S Multiple|athira.com (ATHA) - Forward Price-to-Revenue Multiple|ADXN: Forward P/S Multiple|Alzamend Neuro (ALZN) - Forward P/S Multiple|Forward Price-to-Revenue Multiple CYCN|PTIX (Protagenic) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Forward P/S Multiple cortigent.com (CRGT)|Price-to-Projected Revenue Ratio Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|CARA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Chromocell|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|ITCI - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple LBPH|MRNS (Marinus Pharmaceuticals Inc) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple NKGN (NKGen)|NRBO (NeuroBo Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX (synaptogen.com) - Future Price to Revenue|Trevena - Forward P/S Multiple|Forward Price to Sales VIGL (Vigil Neuroscience)|WENA: Forward P/S Multiple|Cerevel Corp (CERE) - Forward P/S Multiple
